Pancreatic Factor Promotes CNS Remyelination After Injury
Fibroblast growth factor (FGF) 21 promotes remyelination in mice and may be a promising key molecule for treating demyelinating diseases, a new study by scientists at Osaka University shows. Demyelination occurs in diseases such as multiple sclerosis, and is associated with neurological dysfunction.
In normal development, oligodendrocyte precursor cells (OPCs) differentiate into oligodendrocytes, which are required for myelination. OPCs will proliferate around the lesions of demyelination after injury and contribute to spontaneous remyelination, but the molecular mechanism of OPCs proliferation is not fully clarified.
“Factors in the blood cannot reach the normal brain because central nervous system has blood-brain barrier. In demyelination diseases like multiple sclerosis, the blood-brain barrier around the lesion is disrupted,”
she said. Muramatsu suspected that with the breach, factors from peripheral organs secreted into the blood could now reach the brain.
Oligodendrocyte Precursor Cells
To test her hypothesis, her team disrupted the vascular barrier and myelin structures in mice by injecting Lysophosphatidylcholine (LPC). They then looked for circulating factors that promote OPCs proliferation and found FGF21 as a candidate.
Mice treated with LPC showed high levels of FGF21 around demyelinated lesions leading to remyelination. This was not the case in mutant mice that could not express FGF21.
Other mice that received direct administration of FGF21 to demyelinated lesions caused by LPC injection also showed increased remyelination and better recovery of neurological function.
FGF21 knockout mice show inhibition of remyelination and functional recovery after demyelination. Credit: Osaka University
In addition, the researchers found OPCs expressed higher levels of b–klotho, co-receptor for FGF21, following LPC injection. Without this expression, FGF21 could not promote remyelination.
The results suggest that FGF21 has therapeutic potential for demyelinating diseases. FGF21 analogs are already being used for clinical studies on diabetes, which means its development for remyelination could go faster than had it been an untested compound.
“There are many drugs that inhibit demyelination, but none that promote remyelination. FGF21 is a new candidate that deserves more testing. The most important finding is that we show the peripheral milieu promotes central nervous system remyelination,”